Aptose Biosciences (APTO) reported promising early safety and response results from newly diagnosed acute myeloid leukemia patients dosed in Aptose’s Phase 1/2 TUSCANY trial with a 40 mg dose of tuspetinib in combination with standard of care dosing of venetoclax and azacitidine, TUS+VEN+AZA triplet. The TUS+VEN+AZA triplet is being developed as a frontline therapy to treat large, mutationally diverse populations of newly diagnosed AML patients who are ineligible to receive induction chemotherapy.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APTO:
- Aptose Biosciences Initiates TUSCANY Trial for Frontline AML Therapy
- Aptose announces first AML patients dosed in TUSCANY trial
- Biotech Alert: Searches spiking for these stocks today
- Aptose Biosciences Granted Nasdaq Compliance Extension
- Aptose Biosciences granted extension to regain compliance with Nasdaq